Advanced Solid Tumor
Conditions
Keywords
dose escalation, safety, tolerability, advanced solid tumors, pharmacokinetics
Brief summary
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors.
Detailed description
This trial will have a run-in phase to explore the safety and tolerability of YH001 as a single agent for 21 days as DLT observation period then followed by a combination phase to further explore the safety and tolerability of YH001 combined with Toripalimab (anti-PD-1 antibody) for each dose level during dose escalation. The dose escalation will follow the traditional 3 + 3 dose escalation scheme. These subjects will be treated with YH001 and Toripalimab. YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G. Toripalimab will be administered by IV (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle. A single subject will be enrolled at Dose A as starting dose of YH001, and subsequent cohort will be expanded to include 3-6 subjects.
Interventions
DRUGYH001
YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
DRUGToripalimab
Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
Sponsors
Eucure (Beijing) Biopharma Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, aged ≥ 18 years * Have advanced histologically or cytologically confirmed solid tumor * Have progressed on after treatment with standard therapies or intolerant of standard care * At least 1 unidimensional measurable target lesion per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 * Have life expectancy of at least 12 weeks based on investigator's judgement
Exclusion criteria
* Treated with any investigational drug within 4 weeks prior to the fist dose of study drug * Received any anticancer therapy less than 28 days prior to the first administration of study drug or within 5 half-lives of the therapy agent, whichever is shorter. Prior palliative radiotherapy to bone metastases ≤ 2 weeks prior to the first dose of YH001 is acceptable * Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded * Subjects with prior PD-1/L1 treatment intolerate to PD-1/L1 therapy should be excluded * Subjects with a history of ≥ Grade 3 immune-related adverse events (AEs) resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy * Subjects with a history of ≥ Grade 2 pneumonitis resulted from previous immunotherapy or with a SpO2 by pulse oximetry \< 92% at the screening * Subjects requiring systemic treatment with corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Ophthalmologic, nasal and intra-articular injections of steroids are allowed * Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. Exceptions are subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy * Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. But subjects with asymptomatic CNS metastases might be eligible if they have no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and the first dose of YH001 and are currently not receiving corticosteroids * QTc \> 450 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome * Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ Grade 1 per CTCAE v5.0, except alopecia, \< Grade 2 sensory neuropathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events and serious adverse events | From screening up to 1 year | The safety profile of YH001 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 |
| Maximum tolerated dose (MTD) | During Cycle 1 (each cycle is 21 days) | MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle |
| Dose-limiting toxicities (DLT) | During Cycle 1 (each cycle is 21 days) | DLT is defined as a toxicity (adverse event at least possibly related to YH001) occurring during the DLT observation period (the initial 21 days) both in run-in phase of YH001 as single agent and in combination phase of YH001 in combination with Toripalimab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trough concentration before the next dose is administered (Ctrough) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Time to reach maximum serum concentration (Tmax) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Clearance (CL) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Volume of distribution (Vd) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Terminal half-life (T1/2) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Dose proportionality | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Incidence of anti-drug antibodies (ADAs) | Up to 1 year | To assess the immunogenicity of YH001 in combination with Toripalimab |
| Area under the serum concentration versus time curve within one dosing interval (AUCtau) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Objective response rate (ORR) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Duration of response (DOR) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Time to response (TTR) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Progression free survival (PFS) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Overall survival (OS) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Disease control rate (DCR) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Duration of disease control (DDC) | Up to 1 year | To assess the preliminary antitumor activity of YH001 in combination with Toripalimab |
| Incidence of neutralizing antibodies (NAbs) | Up to 1 year | To assess the immunogenicity of YH001 in combination with Toripalimab |
| Steady state AUC | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
| Maximum serum concentration (Cmax) | Up to 1 year | To determine the PK profile of YH001 alone and in combination with Toripalimab |
Countries
Australia
Outcome results
None listed